Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses (AID MORE)
2014-001603-42Phase 3Completed
- Sponsor
- AIL Catania
- Start
- Nov 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of imatinib and dasatinib in chronic myelogenous leukemia (CML), sponsored by AIL Catania. Primary endpoints: Rate of MR4.5 at 12 months of treatment and Rate of confirmed MR4.5 at 12 months of treatment. Started Nov 2014; status: completed.
02
Drugs
imatinibdasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2014-001603-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001603-42.